This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

John M. Kane, MD; Christoph U. Correll, MD; Donald C. Goff, MD; Brian Kirkpatrick, MD, MSPH; Stephen R. Marder, MD; Estelle Vester-Blokland, MD; Wei Sun, PhD; William H. Carson, MD; Andrei Pikalov, MD, PhD; and Sheila Assunção-Talbott, MD, PhD

Published: October 15, 2009

Article Abstract

Objective: Combining antipsychotics is common practice in the treatment of schizophrenia. This study investigated aripiprazole adjunctive to risperidone or quetiapine for treating schizophrenia and schizoaffective disorder.

Method: In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d). The primary outcome measure was the mean change from baseline to endpoint (week 16, last observation carried forward) in the Positive and Negative Syndrome Scale (PANSS) total score.

Results: 323 subjects being treated with either risperidone (n‘ ‰=‘ ‰177) or quetiapine (n‘ ‰=‘ ‰146) were randomly assigned to receive adjunctive aripiprazole (n‘ ‰=‘ ‰168) or placebo (n‘ ‰=‘ ‰155). Baseline characteristics were similar (mean PANSS total score: aripiprazole, 74.5; placebo, 75.9) except for history of suicide attempts (aripiprazole, 27%; placebo, 40%). Nearly 70% of subjects in each arm completed the trial. Adjunctive aripiprazole and placebo groups were similar in the mean change from baseline to endpoint in the PANSS total score (aripiprazole, -8.8; placebo, -8.9; P‘ ‰=‘ ‰.942). The incidence of treatment-emergent adverse events was similar between groups. Mean changes in Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes Akathisia Rating Scale scores were not statistically significantly different. Adjunctive aripiprazole was associated with statistically significantly greater decreases in mean serum prolactin levels from baseline than was adjunctive placebo (-12.6 ng/mL for aripiprazole vs -2.2 ng/mL for placebo; P‘ ‰<‘ ‰.001), an effect that was seen in the risperidone subgroup (-18.7 ng/mL vs -1.9 ng/mL; P‘ ‰<‘ ‰.001) but not in the quetiapine subgroup (-3.01 ng/mL vs +0.15 ng/mL; P‘ ‰=‘ ‰.104).

Conclusions: The addition of aripiprazole to risperidone or quetiapine was not associated with improvement in psychiatric symptoms but was generally safe and well tolerated. Further research is warranted to explore whether antipsychotic combination therapy offers benefits to particular patient populations—for example, in cases of hyperprolactinemia.

Trial Registration: Identifier: NCT00325689

Submitted: February 20, 2009; accepted May 21, 2009.

Corresponding author: John M. Kane, MD, Department of Psychiatry, The Zucker Hillside Hospital, 7559 263rd Street, Glen Oaks, NY 11004-1150 (

Volume: 70

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF